Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

100397

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answers of 30 March 2011, Official Report, column 399W, to the hon. Member for Colne Valley, and of 28 March 2011, Official Report, House of Lords, column WA217, to Lord Morris of Manchester, whether, when the dependents and widows of those who contracted hepatitis C following treatment with NHS blood products, but who died before 29 August 2003, were given the opportunity to apply for Skipton Fund lump sum payments during a two month period in January to March 2011 the fact that (a) registrations made after the 31 March 2011 deadline could be accepted on a case-by-case basis where there was a valid reason for the applicant to have missed the registration deadline and (b) applicants needed only to register with the fund by the deadline and could compile the necessary medical evidence later were communicated through the channels listed in Deposited Paper DEP2011-0543.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	211655
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The decision that claims to the Skipton Fund in respect of people who died before 29 August 2003 could be registered after 31 March 2011 on a case-by-case basis, where there was a valid reason for the applicant to have missed the registration deadline, was communicated by the Skipton Fund on its website. It was not communicated through the other channels listed in Deposited Paper DEP2011-0543.</p><p> </p><p><strong> </strong></p><p> </p><p>The Skipton Fund website still states that it is possible to apply for payments on behalf of the estate of someone who died prior to 29 August 2003, but claimants are asked to contact the Skipton Fund to discuss whether the claimant has a valid reason for missing the original deadline for registering claims of 31 March 2011. <br> <br></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:38:11 answering member 3918 label Biography information for Jane Ellison
	tabling member	1533 label Biography information for Dame Diana Johnson

100400

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to ensure that the NHS improves the diagnosis and treatment of pancreatic cancer.
	tabling member constituency	Birkenhead
	tabling member printed	Mr Frank Field
	uin	211514
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Achieving earlier diagnosis of cancer is key to our ambition to save an additional 5,000 lives per year by 2014-15. We are investing £450 million to achieve early diagnosis of cancer through better public awareness, better screening and better access to key diagnostic tests. However we know that early diagnosis of pancreatic cancer can be very difficult as the symptoms are shared with a wide range of benign conditions.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) Referral Guidelines for Suspected Cancer (2005) are available to help general practitioners assess when it is appropriate to refer patients for suspected cancer, including pancreatic cancer. NICE is in the process of updating the guidelines to ensure that these reflect latest evidence and can continue to support general practitioners (GPs) to identify patients with suspected cancer symptoms and urgently refer them as appropriate. NICE’s anticipated publication date for the revised guidelines is May 2015.</p><p> </p><p> </p><p> </p><p>We understand that NHS England has asked NICE to develop a clinical guideline and quality standard on pancreatic cancer.</p><p> </p><p> </p><p> </p><p>At a local level, it is for individual clinical commissioning groups to promote and enhance the diagnostic capability to deliver better outcomes. Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned at the moment by NHS England. NHS England’s pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services. This service specification has been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe core and developmental service standards.</p><p> </p><p> </p><p> </p><p>NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK into the use of Stereotactic Ablative Radiotherapy (SABR), an innovative radiotherapy treatment. This will allow patients to receive SABR treatment now, where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of these treatments so that in future, if it proves to be effective, they will be available for all relevant patients on the NHS. One of these six trials will be on pancreatic cancer.</p><p> </p><p><strong> </strong></p><p> </p><p>The Department published Improving Outcomes for Upper Gastro-Intestinal Cancers in 2001, which describes best practice in the delivery of services for patients with all types of upper gastro-intestinal cancer, including pancreatic cancer.<br> <br> NICE has recommended gemcitabine as a treatment option for pancreatic cancer in technology appraisal guidance published in May 2001, subject to certain clinical criteria and is currently appraising a number of other pancreatic cancer drugs. Patients have the right to drugs and treatments that have been recommended by NICE technology appraisal guidance for use in the National Health Service, where their doctor believes they are clinically appropriate. <br> <br> A number of drugs to treat pancreatic cancers are also available through the Cancer Drugs Fund.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 16:58:52 answering member 3918 label Biography information for Jane Ellison
	tabling member	478 label Biography information for Lord Field of Birkenhead

100404

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Obesity: Pendle
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many (a) men and (b) women in Pendle constituency were classified as (i) overweight and (ii) obese in each of the last 10 years.
	tabling member constituency	Pendle
	tabling member printed	Andrew Stephenson
	uin	211556
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Data on adult obesity and excess weight (overweight and obese) for Pendle district are available from the ‘Local Health Profiles’ using data from the ‘Active People Survey’ commissioned by Sport England. The data are only available for 2012 and are presented as a total figure for males and females. This data is not collected by parliamentary constituency. The following data are for the area of Pendle district.</p><p> </p><p> </p><p> </p><p>Excess weight defined as the proportion of the adult population who are overweight or obese for Pendle district in 2012 was 67.7% (England 63.8%).</p><p> </p><p> </p><p> </p><p>The proportion of the adult population in Pendle district classified as obese in 2012 was 25.3% (England 23.0%).</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:41:28 answering member 3918 label Biography information for Jane Ellison
	tabling member	4044 label Biography information for Andrew Stephenson

100405

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Obesity: Pendle
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many children in Pendle constituency were classified as (a) overweight and (b) obese in each year since 2006-07.
	tabling member constituency	Pendle
	tabling member printed	Andrew Stephenson
	uin	211555
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Data on childhood obesity are not collected by parliamentary constituency. The following data are for the area of Pendle district. The National Childhood Measurement Programme (NCMP) data collection began in 2006-07 and only collects data on two age groups; reception year (4-5 years) and year 6 (10-11 years).</p><p> </p><p> </p><p> </p><table><tbody><tr><td> </td><td colspan="4"><p>Reception Year (4-5 years)</p></td><td colspan="4"><p>Year 6 (10-11 years)</p></td></tr><tr><td><p> </p></td><td colspan="2"><p>Prevalence of obesity</p></td><td colspan="2"><p>Prevalence of overweight (including obese)</p></td><td colspan="2"><p>Prevalence of obesity</p></td><td colspan="2"><p>Prevalence of overweight (including obese)</p></td></tr><tr><td><p> </p></td><td><p>Children</p></td><td><p>%</p></td><td><p>Children</p></td><td><p>%</p></td><td><p>Children</p></td><td><p>%</p></td><td><p>Children</p></td><td><p>%</p></td></tr><tr><td><p>2006-07</p></td><td><p>94</p></td><td><p>10.84</p></td><td><p>191</p></td><td><p>22.03</p></td><td><p>50</p></td><td><p>13.59</p></td><td><p>99</p></td><td><p>26.9</p></td></tr><tr><td><p>2007-08</p></td><td><p>89</p></td><td><p>10.06</p></td><td><p>193</p></td><td><p>21.81</p></td><td><p>152</p></td><td><p>18.36</p></td><td><p>251</p></td><td><p>30.31</p></td></tr><tr><td><p>2008-09</p></td><td><p>82</p></td><td><p>7.98</p></td><td><p>219</p></td><td><p>21.32</p></td><td><p>159</p></td><td><p>16.31</p></td><td><p>279</p></td><td><p>28.62</p></td></tr><tr><td><p>2009-10</p></td><td><p>102</p></td><td><p>9.51</p></td><td><p>253</p></td><td><p>23.58</p></td><td><p>175</p></td><td><p>17.82</p></td><td><p>307</p></td><td><p>31.26</p></td></tr><tr><td><p>2010-11</p></td><td><p>106</p></td><td><p>9.84</p></td><td><p>256</p></td><td><p>23.77</p></td><td><p>163</p></td><td><p>17.25</p></td><td><p>291</p></td><td><p>30.79</p></td></tr><tr><td><p>2011-12</p></td><td><p>115</p></td><td><p>10.48</p></td><td><p>271</p></td><td><p>24.7</p></td><td><p>192</p></td><td><p>19.12</p></td><td><p>352</p></td><td><p>35.06</p></td></tr><tr><td><p>2012-13</p></td><td><p>151</p></td><td><p>12.46</p></td><td><p>313</p></td><td><p>25.83</p></td><td><p>188</p></td><td><p>19.54</p></td><td><p>339</p></td><td><p>35.24</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><em>Source</em>: Health and Social Care Information Centre, National Childhood Measurement Programme.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:23:51 answering member 3918 label Biography information for Jane Ellison
	tabling member	4044 label Biography information for Andrew Stephenson

100410

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the letter dated 7 March 2014 from the Minister for Public Health to the hon. Member for Kingston upon Hull North (reference POC4 845965) if he will place in the Library all documents in the possession of his Department relating to the advice received from an independent group of experts when the Skipton Fund was first established in 2003-04 in relation to the practicality of the State 1/Stage 2 Hepatitis C distinction.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	211638
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>We will arrange for all of the documents relating to the advice received from the group of independent experts which provided advice on the medical trigger for Skipton Fund stage 2 payments in 2003-04, to be placed in the Library by 14 November 2014.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:17:54 answering member 3918 label Biography information for Jane Ellison
	tabling member	1533 label Biography information for Dame Diana Johnson

100413

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prostate Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to improve the diagnosis and treatment of prostate cancer.
	tabling member constituency	Birkenhead
	tabling member printed	Mr Frank Field
	uin	211632
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>Achieving earlier diagnosis of cancer is key to our ambition to save an additional 5,000 lives per year by 2014-15. We are investing £450 million to achieve early diagnosis of cancer through better public awareness, better screening and better access to key diagnostic tests.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) Referral Guidelines for Suspected Cancer (2005) are available to help general practitioners (GPs) assess when it is appropriate to refer patients for suspected cancer, including prostate cancer. NICE is in the process of updating the guidelines to ensure that these reflect latest evidence and can continue to support GPs to identify patients with suspected cancer symptoms and urgently refer them as appropriate. NICE’s anticipated publication date for the revised guidelines is May 2015.</p><p> </p><p> </p><p> </p><p>At a local level, it is for individual clinical commissioning groups to promote and enhance the diagnostic capability to deliver better outcomes. Surgery, radiotherapy and chemotherapy treatments that may be used for prostate cancer are commissioned at the moment by NHS England. NHS England’s prostate cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective prostate cancer services. This service specification has been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe core and developmental service standards.</p><p> </p><p> </p><p> </p><p>NICE published an updated clinical guideline on the diagnosis and treatment of prostate cancer in January 2014. NICE has recommended docetaxel, abiraterone and enzalutamide as treatment options for some types of prostate cancer, subject to certain clinical criteria and is currently appraising a number of other prostate cancer drugs. Patients have the right to drugs and treatments that have been recommended by NICE technology appraisal guidance for use in the National Health Service, where their doctor believes they are clinically appropriate. A number of drugs to treat prostate cancer are available through the Cancer Drugs Fund.</p><p> </p><p> </p><p> </p><p>This Government is also investing in innovative radiotherapy treatments to improve outcomes for those with cancer. NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK into the use of Stereotactic Ablative Body Radiotherapy (SABR). This will allow patients to receive SABR treatment now, where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of these treatments so that in future, if it proves to be effective, they will be available for all relevant patients on the NHS. Two of these six trials will be on prostate cancer.</p><p> </p><p> </p><p> </p><p>We have also invested £23 million across 50 United Kingdom centres aimed at increasing the capacity of radiotherapy centres in England to deliver Intensity Modulated Radiotherapy (IMRT). We committed to achieving the ambition of 24% of all radiotherapy to be delivered through more accurate IMRT, and we are now seeing 35% of all radical radiotherapy treatments delivered using this method compared to 5% in 2010.</p><p> </p><p> </p><p> </p><p>The National Prostate Cancer Audit (NPCA) began collecting data in April 2014 and is due to publish the first of four annual reports during November 2014. The NPCA is the first national clinical audit of the care that men receive following a diagnosis of prostate cancer. It is designed to collect information about the diagnosis, management and treatment of every patient newly diagnosed with prostate cancer in England and Wales, and their outcomes. The findings from the audit will contribute to changes in clinical practice ensuring that patients receive the best care possible and experience an improved quality of life. The audit is funded by the Department and has been commissioned by the Healthcare Quality Improvement Partnership.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 16:57:06 answering member 3918 label Biography information for Jane Ellison
	tabling member	478 label Biography information for Lord Field of Birkenhead

100422

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dietary Supplements
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent representations the Government has made to the European Commission on the future regulation of health food supplements.
	tabling member constituency	Belfast North
	tabling member printed	Mr Nigel Dodds
	uin	211418
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The United Kingdom has not recently made any representations to the European Commission on the future of health food supplements.</p><p> </p><p> </p><p> </p><p>Officials continue to engage at European Commission Expert Working Group meetings to ensure that any future changes to legislation are proportionate and based on evidence, so that consumers have confidence in what they buy, while maintaining a wide choice of safe products.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:25:55 answering member 3918 label Biography information for Jane Ellison
	tabling member	1388 label Biography information for Lord Dodds of Duncairn

100423

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Alcoholic Drinks: Labelling
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect of mandatory labelling on all alcoholic products on the incidence of foetal alcohol spectrum disorders; and if he will make a statement.
	tabling member constituency	Hazel Grove
	tabling member printed	Sir Andrew Stunell
	uin	211414
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The Government is committed to improving the labelling of alcoholic drinks, including a warning to avoid alcohol for women who are pregnant or trying to conceive. It is not mandatory to include warnings on drinking in pregnancy on labels. However, as part of the Public Health Responsibility Deal, alcohol retailers and producers have a responsibility to help raise this awareness and have committed to putting an agreed warning or a pregnancy warning logo on 80% of labels on bottles and cans.</p><p> </p><p>An independent market survey has been carried out which we expect to be published shortly.</p><p> </p><p> </p><p> </p><p>The evidence is that health information on labels should not be considered a standalone measure, but part of broader efforts to raise consumer awareness and education on the health risks linked to alcohol consumption.</p><p> </p><p> </p><p> </p><p>This is supported by research commissioned by the Department in 2005 to review the evidence around the effectiveness of alcohol harm reduction communications and related campaigns.</p><p> </p><p><strong> </strong></p><p> </p><p>The Chief Medical Officer is currently overseeing a United Kingdom-wide review of all alcohol guidelines so that people can make informed choices about their drinking at all stages of their lives.</p><p> </p><p> </p><p> </p><p>The review will specifically include consideration of health risks for women from alcohol consumption. We expect to be able to consult on new draft guidelines by summer 2015.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:00:37 answering member 3918 label Biography information for Jane Ellison
	tabling member	445 label Biography information for Lord Stunell

100426

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cord Blood
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent discussions his Department has had with NHS Trusts on (a) increasing the number of hospitals that are able to collect umbilical cord blood for transport and (b) promoting the donation of umbilical cord blood for transplant.
	tabling member constituency	Wolverhampton South West
	tabling member printed	Paul Uppal
	uin	211439
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>NHS Blood and Transport (NHSBT) manages the NHS Cord Blood Bank and provides specialist services related to the provision of stem cells which can turn into blood cells for the treatment of blood cancers. This service is an integral part of the Anthony Nolan and NHS Stem Cell Registry. NHSBT is also responsible for raising awareness of these issues, in collaboration with its delivery partners. NHSBT has informed the Department that it has no plans to open new collection centres at present.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:40:05 answering member 3918 label Biography information for Jane Ellison
	tabling member	4078 label Biography information for Paul Uppal

100880

	registered interest
	date	24/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Public Health: Business
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the emphasis placed on tackling and preventing lifestyle-related diseases in the NHS Five Year Forward View, published in October 2014, whether he has any plans to review and reform the voluntary responsibility deal.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	211871
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The emphasis placed on tackling and preventing lifestyle-related diseases in the NHS Five Year Forward View underlines the importance of the Public Health Responsibility Deal and the part it plays in supporting people to make healthier choices and tackle the behaviours which lead to chronic health conditions. Over 700 community, voluntary, public sector (National Health Service as well as national and local Government), public health and commercial organisations have signed up to play their part in improving public health.</p><p> </p><p> </p><p> </p><p>The Deal is already focussed on tackling many of the key causes of lifestyle-related ill health outlined in the NHS Five Year Forward View, including obesity, smoking and harmful drinking. The Deal’s pledges tackle a wide range of issues, including: healthier diets (e.g. reformulation for reduced salt levels, elimination of trans-fats and calorie reduction); fostering a culture of responsible drinking (e.g. lower alcohol by volume products, alcohol labelling, increasing awareness of alcohol units); increasing physical activity levels (e.g. physical activity in the workplace and active travel) and improving the health of their staff (e.g. accreditation of occupational health services, supporting employees with mental health conditions in the workplace, smoking cessation and healthier staff restaurants). The Deal will continue to play an important part in delivering these ambitions.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/10/2014 17:09:23 answering member 3918 label Biography information for Jane Ellison
	tabling member	4036 label Biography information for Luciana Berger